Company Statement: Elan announces transactions: decisively transforming the company
MLex Summary: Elan announced its two new acquisitions - the buy-out of AOP Orphan, an Austrian orphan disease company, and 48 percent of Newbridge Pharmaceuticals, a start-up specialty pharmaceutical company. It also announced a share repurchase...To view the full article, register now.
Already a subscriber? Click here to view full article